Sánchez VM

Language: Spanish
References: 17
Page: 13-16
PDF size: 97.61 Kb.

ABSTRACT

Cervical cancers represent a public health problem worldwide, which needs an early intervention and has a causal relation between Human Papilloma Virus (HPV) and cervical cancer . HPV types 16 and 18, are the two high-risk HPVs that cause about 70% of precancerous lesions and cervical cancers.
Studies on intrauterine devices suggest that they do not modify the prevalence of HPV infection, but its progression to cervical cancer.
Many studies published on intrauterine devices (IUDs) suggest that they cannot modify the prevalence of HPV infection, but they can modify the cervical cancer progress.

REFERENCES

1. Agarwal K, Sharma U, Acharya V. (2004) Microbial and cytopathological study ofintrauterine contraceptive device users. Indian J Med Sci. 58 (9):394-99. En línea: https://www.ncbi.nlm.nih.gov/pubmed/15470281

2. Averbach S. et al. (2017). The effect of intrauterine devices on acquisition and clearance of human papillomavirus. Am J Obstet Gynecol 216:386.e1-5.En linea: http://dx.doi.org/10.1016/j.ajog.2016.11.1053

3. Brebi P. et al. (2013) Infección por el virus del papiloma humano en el hombre y su relación conel cáncer: estado actual y prospectivas. Rev Int Androl.;11(1):25-30. En línea: http://dx.doi.org/10.1016/j.androl.2012.09.001

4. Castellsagué X. et al. (2011) Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 12(11):1023-31. En línea: DOI: http://dx.doi.org/10.1016/S1470-2045(11)70223-6

5. Cortés-Alaguero C. et al. (2017). Do clinical data and human papilloma virus genotype influence spontaneous regression in grade I cervical intraepithelial neoplasia?. J Turk Ger Gynecol Assoc 2017; 18: 1-8. En Línea: DOI: 10.4274/jtgga.2016.0138

6. DeCherney A. 2014. Diagnóstico y Tratamiento Ginecoobstetricos. Mexico DF. McGRAW-HILL.

7. Engineer AD, Misra JS, Tandon P. (1981) Long-term cytologic studies of copper-IUD users. Acta Cytol. 25 (5):550-56. En línea: https://www.ncbi.nlm.nih.gov/pubmed/6945020

8. Ganacharya S, Bhattoa HP, Batár I. (2006). Pre-malignant and malignant cervical pathologiesamong inert and copper-bearing intrauterine contraceptive device users: a 10-year follow-up study. Eur J Contracept Reprod Health Care.11(2):89-97. En Linea: DOI: 10.1080/13625180500539513

9. Lassise DL. et al (1991). Invasive cervical cancer and intrauterine device use. Int J Epidemiol. 20(4):865-70. En Linea: https://doi.org/10.1093/ije/20.4.865

10. Misra JS, et al. (1991) Cervical carcinogenesis and contraception. Diagn Cytopahtol. 7(4): 55056. En línea: DOI: 10.1002/dc.2840070405

11. Moschos E, Twickler DM. (2011). Intrauterine devices in early pregnancy: findings on ultrasoundand clinical outcomes. Am J Obstet Gynecol 204:427.e1-6. En línea: http://dx.doi.org/10.1016/j.ajog.2010.12.058

12. Mulcahy N. (2011). IUDs Reduce Risk for Cervical Cancer. Medscape Medical News. En línea: http://www.medscape.com/viewarticle/749595

13. OMS. (2015) Papilomavirus humanos (PVH) y cáncer cervico-uterino. Nota descriptiva N°380. Centro de prensa. En línea: http://www.who.int/mediacentre/factsheets/fs380/es/

14. Petry KU. (2011). Loops in the natural history of cervical cancer. The Lancet Oncology.12(11):986. En Linea: DOI: http://dx.doi.org/10.1016/S1470-2045(11)70255-8

15. Schiffman M. et al. (2007). Human papillomavirus and cervical cancer. Lancet. 370(9590):890907. En Linea: doi: 10.1128/CMR.16.1.1-17.2003

16. Scott, M. E. et al. (2013). Cervical Cytokines and Clearance of Incident Human Papillomavirus Infection: Hawaii HPV Cohort Study. International Journal of Cancer. Journal International DuCancer, 133(5), 1187–1196. http://doi.org/10.1002/ijc.28119

17. Trottier H, Franco E. (2006). Human papillomavirus and cervical cancer: burden of illness andbasis for prevention. Am J Manag Care. 12 17 Suppl:S462-72. En línea: https://www.ncbi.nlm.nih.gov/pubmed/17203990.